DLL3 靶点蛋白|抗体药物|临床药物信息

DLL3信息

英文名称：Delta-like protein 3
中文名称：δ样蛋白-3
靶点别称：Delta-Like Protein 3，Delta3，Delta-Like 3，Drosophila Delta Homolog 3，SCDO1，Delta-Like 3 (Drosophila)，DLL3，Delta (Drosophila)-Like 3，Delta Like Canonical Notch Ligand 3

上市药物数量：0
临床药物数量：4
最高研发阶段：临床二期

DLL3产品列表

筛选结果

产品库

物种

标签

属性

Protein (13)

标记

货号	物种	产品描述
DL3-H5255	Human	Human DLL3 Protein, Fc Tag (MALS verified)
DL3-H52H4	Human	Human DLL3 Protein, His Tag (MALS verified)
DL3-C52H3	Cynomolgus	Cynomolgus DLL3 Protein, His Tag
DL3-HF253	Human	FITC-Labeled Human DLL3 Protein, Fc Tag
DL3-HF2H4	Human	FITC-Labeled Human DLL3 Protein, His Tag
DL3-R52H3	Rat	Rat DLL3 Protein, His Tag
DL3-R52H4	Rhesus macaque	Rhesus macaque DLL3 Protein, His Tag
DL3-H82E4	Human	Biotinylated Human DLL3 Protein, His,Avitag™ (MALS verified)
DL3-H82F5	Human	Biotinylated Human DLL3 Protein, Fc,Avitag™
DL3-M53H9	Mouse	Mouse DLL3 Protein, His Tag
DL3-H52Ha	Human	Human DLL3 (353-492) Protein, His Tag
DL3-H52Hy	Human	Human DLL3 (176-492) Protein, His Tag
DL3-H52Hz	Human	Human DLL3 (312-492) Protein, His Tag

DL3-H52H4|Human DLL3 Protein, His Tag (MALS verified)

132XXXXXXX8

14人赞

该蛋白前期验证时发现有很好的结合活性，将包被浓度降低后仍较稳定的Emax，后期正式筛选过程中也是一如既往的稳定，内部尝试发现还是Acro的蛋白优秀。
>
2021-12-25

DL3-H5255|Human DLL3 Protein, Fc Tag (MALS verified)

132XXXXXXX8

17人赞

前期申请了蛋白和相应的抗体试用装进行了活性鉴定，显示很好的结合活性，故大批量订购开展小鼠免疫。
>
2021-12-25

DL3-H52H4|Human DLL3 Protein, His Tag (MALS verified)

132XXXXXXX8

1人赞

本产品一直用于高通量筛选，直接包被的浓度可将至0.5ug/ml，Emax可稳定在2.5~3，使用专利抗体与之结合的EC50也验证了其活性良好和稳定。
2021-12-25

查看更多评论

DLL3 分子别名

Delta3,delta-like 3 (Drosophila),delta-like protein 3,DLL3,Pudgy,SCDO1,SCDO1delta3

DLL3 分子背景

Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands.May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues.

DLL3 前沿进展

DLL3临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
89Zr-DFO-SC16.56	89Zr-DFO-SC16.56	临床一期	Memorial Sloan Kettering Cancer Center	小细胞肺癌	详情
HPN-328	HPN-328	临床二期	Harpoon Therapeutics	小细胞肺癌	详情
Tarlatamab	AMG-757	临床二期	安进	小细胞肺癌, 前列腺癌	详情
Rovalpituzumab tesirine	SC0001SCX; SC16LD6.5; SC0001-SCX; SC-0002; P256HB60FF	临床一期	艾伯维, Stemcentrx	实体瘤, 小细胞肺癌, 胶质母细胞瘤, 甲状腺髓样癌, 前列腺癌, 神经内分泌癌, 黑色素瘤	详情

会议日历

会议一览

DLL3